TG Therapeutics, Inc.
Financials
Valuation Metrics
TG Therapeutics, Inc.'s Market Cap is $8.71B. At end of 2025 it was $4.26B. Ranked #1014 of 3,121 in US market (top 32%), #328 of 1,463 on NASDAQ (top 22%), #54 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.71B | US#1,014/3,121 Sec#54/266 |
| Revenue | $800M | US#2,008/3,121 Sec#61/266 |
| Net Income | $441M | US#893/3,121 Sec#29/266 |
| Total Assets | $1.64B | US#2,214/3,121 Sec#65/266 |
| Net Assets | $604M | US#2,106/3,121 Sec#96/266 |
| Employees | 399 | US#2,340/3,121 Sec#94/266 |
| Value | ||
| P/E | 19.72x | US#1,111/3,121 Sec#33/266 |
| P/B | 14.41x | US#2,723/3,121 Sec#206/266 |
| PEG | 0.03x | US#85/3,121 Sec#7/266 |
| P/S | 10.89x | US#2,709/3,121 Sec#116/266 |
| EV/EBITDA | 66.91x | US#2,407/3,121 Sec#75/266 |
| FCF Yield | -0.01% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | 73.08% | US#60/3,121 Sec#5/266 |
| ROA | 26.93% | US#45/3,121 Sec#9/266 |
| Op. Margin | 17.05% | US#1,089/3,121 Sec#44/266 |
| Revenue Growth | 76.08% | US#139/3,121 Sec#40/266 |
| Earnings Growth | 630.24% | US#58/3,121 Sec#5/266 |
| Financial Health | ||
| Debt Ratio | 171.42% | US#1,640/3,121 Sec#194/266 |
| Total Debt | $754M | US#1,685/3,121 Sec#53/266 |
| FCF | $-560000.00 | US#2,323/3,121 Sec#87/266 |
| Cash | $483M | US#1,100/3,121 Sec#58/266 |
| Current Ratio | 4.27x | US#548/3,121 Sec#163/266 |
| Net Debt/EBITDA | 2.03x | US#1,324/3,121 Sec#58/266 |
| Performance | ||
| 1Y Return | 74.39% | US#322/3,121 Sec#81/266 |
| 1M Return | 10.02% | US#188/3,121 Sec#22/266 |
| From 52W High | -4.10% | US#293/3,121 Sec#23/266 |
| 1Y MDD | -26.85% | US#1,178/3,121 Sec#66/266 |
| Trading | ||
| Volume | 4,354,419 shares | US#1,086/3,121 Sec#110/266 |
| Trading Value | $248M | US#945/3,121 Sec#65/266 |
| Per Share | ||
| EPS | $2.88 | US#1,091/3,121 Sec#31/266 |
| BPS | $3.95 | US#2,368/3,121 Sec#141/266 |
Company Info
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.